Related Experiment Video
Updated: May 31, 2026
12:04
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
Ceramidases in hematological malignancies: senseless or neglected target?
Gemma Fabrias1, Carmen Bedia, Josefina Casas
1Spanish National Research Council, Research Unit on Bioactive Molecules, Departament de Química Biomèdica, Institut de Química Avançada de Catalunya, Barcelona, Spain. gfdqob@cid.csic.es
Anti-Cancer Agents in Medicinal Chemistry
|June 29, 2011
Summary
Ceramidase inhibitors show promise for treating cancers, including hematologic malignancies. Targeting ceramidases may enhance chemotherapy effectiveness and combat cancer relapses.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Ceramidases are enzymes that break down ceramides, playing a crucial role in cell protection.
- Dysregulated ceramidase activity is linked to various human diseases, particularly cancer initiation and progression.
- Acid ceramidase is implicated in tumor response to cancer therapies.
Purpose of the Study:
- To explore the potential of ceramidase inhibitors as anticancer agents.
- To investigate the role of sphingolipid metabolism in hematological malignancies.
- To evaluate the feasibility of using ceramidase inhibitors in treating hematologic cancers.
Main Methods:
- Review of existing literature on ceramidases, cancer, and hematologic malignancies.
- Analysis of the role of sphingolipid metabolism in cancer development.
- Assessment of indirect evidence for ceramidase inhibitor efficacy in hematologic cancers.
Main Results:
- Acid ceramidase inhibitors are recognized for their anticancer potential, used alone or with other treatments.
- Sphingolipid metabolism is a viable therapeutic target for hematologic malignancies.
- Indirect evidence suggests ceramidase inhibition could enhance existing chemotherapy for hematologic cancers and prevent relapse.
Conclusions:
- Ceramidase inhibitors represent a promising therapeutic strategy for various cancers.
- Targeting ceramidases, particularly acid ceramidase, may offer new avenues for treating hematologic malignancies.
- Further research is needed to validate the clinical application of ceramidase inhibitors in hematologic cancer therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...